Active immunotherapy for acute lymphoblastic leukaemia

…, A Cattan, JR Schlumberger, M Hayat, F De Vassal - The Lancet, 1969 - Elsevier
Active immunotherapy (with BCG and/or vaccination from a pool of allogeneic leukæmic "
lymphoblasts " pretreated with formalin or irradiated in vitro) has been given to patients with …

Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and …

…, G Peytavin, JL Misset, S Brienza, F De Vassals… - Biomedicine & …, 1989 - Elsevier
… rkmissions duns le cancer colorecta~ et a induit quelques gukkons dans des cas dede
gudrisons de souris porteuses de Ieuckmie LIZlO. qu’aucune autre combinaison des sels de

Vindesine: a new vinca alkaloid

M Bayssas, J Gouveia, F De Vassal, JL Misset… - Cancer Chemo-and …, 1980 - Springer
Vindesine (VDS) is an analogue of the vinca alkaloids. Its spectrum of antitumoral activity is
similar to that of vincristine (VCR), but with milder experimental neurotoxicity, and it inhibits …

Holistic asset allocation for private individuals

GB Fowler, V De Vassal - The Journal of Wealth Management, 2006 - pm-research.com
In Information Leakage in Energy Derivatives around News Announcements , in the Summer
2020 issue of The Journal of Derivatives, authors Marc Bohmann and Vinay Patel (both of …

Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas

…, M Musset, M Schneider, JL Amiel, F De Vassal - Cancer, 1974 - Wiley Online Library
The preliminary results obtained with VM 26 and VP 16213 (two semisynthetic derivatives
from epipodophyllotoxin) on leukemias and hematosarcomas are described. These …

[HTML][HTML] Pharmacologic factors and manipulation of immunity systemic adjuvants in cancer therapy

…, L Schwarzenberg, P Pouillart, F De Vassal - Cancer Treat …, 1978 - books.google.com
Because of the experimental and clinical studies which have been extensively conducted
with bacillus Calmette-Guérin (BCG) as a systemic adjuvant in cancer immunotherapy, we …

[HTML][HTML] Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and Hodgkin's …

G Mathé, JL Misset, F De Vassal, J Gouveia… - Cancer Treat …, 1978 - books.google.com
Vindesine, an analog of vinblastine and vincristine, has been submitted to a phase II trial, the
results of which are judged in terms of remission induction. A high proportion of remissions …

Risk diversification benefits of multiple-stock portfolios

V De Vassal - Journal of portfolio management, 2001 - search.proquest.com
A useful framework for explaining the risk-return benefits of adding stocks to a portfolio is
provided. The analysis uses Monte Carlo techniques to simulate total returns of equity portfolios …

New antigens in human leukaemic cells, and antibody in the serum of leukaemic patients

JF Dore, L Marholev, HC De La Noue, F De Vassal… - The Lancet, 1967 - Elsevier
51 patients with leukæmia or lymphoma, were subjected, before treatment, to a search for
serum antibodies against their own leukæmic cells. Four tests were used: cytotoxicity, …

Relationships and genetic diversity within the accessions related to Malvasia held in the Domaine de Vassal grape germplasm repository

T Lacombe, JM Boursiquot, V Laucou… - … journal of enology …, 2007 - Am Soc Enol Viticulture
Several types of grape varieties have been traditionally considered under the generic term of
Malvasia, often with a complementing name related to geographic origin. We examined 56 …